Back
$36M IPO
Genenta Science S.p.A. is a clinical-stage biotech company pioneering the development of immunogenic therapy for solid tumours. The current focus is on GBM through the lead product Temferon™️.
Growth Capital supported Genenta’s management team in strategic choices related to fundraising and listing on Nasdaq.
On 15 December 2021, the company listed on the main index of US technology stocks, raising around USD 36 million.
Visit website
Growth Capital supported Genenta’s management team in strategic choices related to fundraising and listing on Nasdaq.
On 15 December 2021, the company listed on the main index of US technology stocks, raising around USD 36 million.
